Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Joshua Barnett & Sofia Pappa. (2023) Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety. Patient Preference and Adherence 17, pages 1603-1610.
Read now
Read now
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Read now
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, Paul Seerden, Stynke Castelein & Henderikus Knegtering. (2022) One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives. Patient Preference and Adherence 16, pages 615-624.
Read now
Read now
Maryia Zhdanava, H Lynn Starr, Todor I Totev, Patrick Lefebvre, Aditi Shah, Kristy Sheng & Dominic Pilon. (2022) Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey. Neuropsychiatric Disease and Treatment 18, pages 2003-2019.
Read now
Read now
Francesco Pietrini, Lorenzo Tatini, Gabriele Santarelli, Dario Brugnolo, Marco Squillace, Bernardo Bozza, Andrea Ballerini, Valdo Ricca & Giulio D’Anna. (2021) Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study. International Journal of Psychiatry in Clinical Practice 25:3, pages 307-315.
Read now
Read now
Martin Lambert, Pedro Sanchez, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller & Katalin Pungor. (2020) Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia. Neuropsychiatric Disease and Treatment 16, pages 3197-3208.
Read now
Read now
Articles from other publishers (18)
Khadija Benallel, Wafaa Mansouri, Jalal Salim, Roukaya Benjelloun & Mohamed Kadiri. (2023) Prescribing habits of Moroccan psychiatrists toward patients with schizophrenia: about 72 practitioners. Middle East Current Psychiatry 30:1.
Crossref
Crossref
Renato de Filippis, Filippo Antonio Staltari, Matteo Aloi, Elvira Anna Carbone, Marianna Rania, Laura Destefano, Luca Steardo Jr., Cristina Segura-Garcia & Pasquale De Fazio. (2023) Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study. Brain Sciences 13:4, pages 577.
Crossref
Crossref
Antonio Vita, Andrea Fagiolini, Giuseppe Maina, Claudio Mencacci, Edoardo Spina & Silvana Galderisi. (2023) Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic. Annals of General Psychiatry 22:1.
Crossref
Crossref
Ilaria Riboldi, Daniele Cavaleri, Chiara A Capogrosso, Cristina Crocamo, Francesco Bartoli & Giuseppe Carrà. (2022) Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia. Psychology Research and Behavior Management Volume 15, pages 3915-3929.
Crossref
Crossref
Hannah A. Blair. (2022) Paliperidone palmitate intramuscular 6-monthly formulation in schizophrenia: a profile of its use. Drugs & Therapy Perspectives 38:8, pages 335-342.
Crossref
Crossref
Lulu Lian, David D. Kim, Ric M. Procyshyn, Diane H. Fredrikson, Diana Cázares, William G. Honer & Alasdair M. Barr. (2021) Efficacy of long‐acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta‐analysis. Early Intervention in Psychiatry 16:6, pages 589-599.
Crossref
Crossref
Rosaria Di Lorenzo, Anita Iorio, Margherita Pinelli, Federica Maria Magarini, Mattia Marchi, Andrea Sacchetti, Chiara Calogero, Gian Galeazzi, Paola Ferri, Sergio Rovesti & Alessandro Minarini. (2022) Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs. Neuropsychiatric Disease and Treatment Volume 18, pages 829-846.
Crossref
Crossref
Dean Najarian, Panna Sanga, Steven Wang, Pilar Lim, Arun Singh, Mary Jane Robertson, Kristin Cohen, Alain Schotte, Ruth Milz, Raja Venkatasubramanian, Huybrecht T’Jollyn, David P Walling, Silvana Galderisi & Srihari Gopal. (2022) A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. International Journal of Neuropsychopharmacology 25:3, pages 238-251.
Crossref
Crossref
Azizah Attard, John Wakelam, Josephine Broyd, David Taylor & Jonathan Hafferty. (2022) Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital. Therapeutic Advances in Psychopharmacology 12, pages 204512532211130.
Crossref
Crossref
Katalin Pungor, Pedro Sanchez, Sofia Pappa, Jerome Attal, Karolina Leopold, Geertje Steegen, Antonio Vita, Carol Marsella, Caroline Verrijcken, Marjolein Lahaye & Annette Wooller. (2021) The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia. BMC Psychiatry 21:1.
Crossref
Crossref
Giovanni Ostuzzi & Corrado Barbui. (2021) Expanding access to long-acting antipsychotics in low-income and middle-income countries. The Lancet Psychiatry 8:12, pages 1034-1035.
Crossref
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Crossref
Giovanni OstuzziFederico BertoliniCinzia Del GiovaneFederico TedeschiChiara BovoChiara GastaldonMichela NoséFilippo OgheriDavide PapolaMarianna PurgatoGiulia TurriniChristoph U. CorrellCorrado Barbui. (2021) Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. American Journal of Psychiatry 178:5, pages 424-436.
Crossref
Crossref
Gerhard Gründer, Philipp Bauknecht, Stefan Klingberg, Karolina Leopold, Michael Paulzen, Stefanie Schell, Katarina Stengler & Stefan Leucht. (2020) Treatment Goals for Patients with Schizophrenia — A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry 54:02, pages 53-59.
Crossref
Crossref
Maryia Zhdanava, Dee Lin, Marie-Hélène Lafeuille, Isabelle Ghelerter, Laura Morrison, Patrick Lefebvre & Kruti Joshi. (2021) Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse. Clinical Therapeutics 43:3, pages 535-548.
Crossref
Crossref
Blanca Fernández-Abascal, Maria Recio-Barbero, Margarita Sáenz-Herrero & Rafael Segarra. (2021) Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Therapeutic Advances in Psychopharmacology 11, pages 204512532199127.
Crossref
Crossref
Mary V. Seeman. (2019) The Gut Microbiome and Treatment-Resistance in Schizophrenia. Psychiatric Quarterly 91:1, pages 127-136.
Crossref
Crossref
Hsiao-Fen Hsu, Chia-Chan Kao, Ti Lu, Jeremy C. Ying & Sheng-Yu Lee. (2019) Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services. Journal of Clinical Medicine 8:6, pages 823.
Crossref
Crossref